Table of Contents
Volume 5 | Issue 1
Publication Date: May 2005- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Editorial | ||
12 |
Making Sense out of Antisense Thymidylate Synthase Edward Chu |
|
Researches in Brief | ||
21-23 |
Recent Results and Ongoing Trials with Panitumumab (ABXEGF), a Fully Human Anti–Epidermal Growth Factor Receptor Antibody, in Metastatic Colorectal Cancer Preeta Tyagi, Vinay Jain, Edward Chu |
|
24-26 |
Vatalanib (PTK787/ZK 222584) in Combination with FOLFOX4 Versus FOLFOX4 Alone as First-Line Treatment for Colorectal Cancer: Preliminary Results from the CONFIRM-1 Trial CIG Media Group |
|
Comprehensive Reviews | ||
27-36 |
Edotecarin: A Novel Topoisomerase I Inhibitor M. Wasif Saif, Robert B. Diasio |
|
37-49 |
Immunologic Therapies for Gastrointestinal Cancers Benjamin Levy, John F. Deeken, Greg Holt, John L. Marshall |
|
Original Contribution | ||
50-56 |
Results of a Phase II Open-Label Study of Capecitabine in Combination with Irinotecan as First-Line Treatment for Metastatic Colorectal Cancer Thomas Cartwright, Timothy Lopez, Svetislava J. Vukelja, Carlos Encarnacion, Kristi A. Boehm, Lina Asmar |
|
Translational Medicine | ||
57-60 |
The rTS Signaling Pathway as a Target for Drug Development Bruce J. Dolnick |
|
Case Report | ||
61-64 |
Severe Irinotecan-Induced Toxicities in a Patient with Uridine Diphosphate Glucuronosyltransferase 1A1 Polymorphism Ranee Mehra, John Murren, Gina Chung, Brian Smith, Amanda Psyrri |
|